ULTOMIRIS
Google image searchProduct monograph
Active ingredient
ravulizumab, 300 MG/3 ML
DIN: 02533448
Dosage form(s): SOLUTION
Route(s) of administration: INTRAVENOUS
Description: SINGLE-USE VIAL
Schedule: Prescription / Schedule D
Company: ALEXION PHARMA GMBH
Date: 19-APR-2023
ATC:
- L04 — IMMUNOSUPPRESSANTS (ATC, ATC/DDD, )
- L04A — IMMUNOSUPPRESSANTS (ATC, ATC/DDD)
- L04AJ — Complement inhibitors (ATC, ATC/DDD)
- L04AJ02 — RAVULIZUMAB (ATC/DDD)
